The overall objective of the Clinical Pharmacology Shared Resource is to advance clinical cancer research by providing clinical pharmacology services to Masonic Cancer Center (MCC) members. This objective is closely aligned with the goal ofthe MCC to translate research findings into safe and highly effective cancer treatments. In the last Cancer Center Support Grant renewal, the Clinical Pharmacology Shared Resource was supported as a developing shared resource. In this application, it is included as a full shared resource. The Shared Resource provides 1) drug analysis services and 2) consulting services for pharmacokinetics, pharmacodynamics, and pharmacogenetics. The Clinical Pharmacology Shared Resource was established in 2008 as a developing shared resource using resources contained in the existing Clinical Pharmacology Analytical Laboratory, which was formed in 2003 in the College of Pharmacy. Personnel in the Shared Resource develop assays to measure drug and metabolite concentrations using HPLC, GC-MS, and LC-MS/MS and validate them to ensure accurate measurement across broad ranges of concentrations. The Shared Resource processes, stores, and ships samples for local and national pharmacology studies. The faculty also provide consulting services to support the design, conduct, and analysis of clinical pharmacology studies and conduct pharmacokinetic, pharmacodynamic, and pharmacogenetic analyses. These services are highly cost efficient because most clinical investigators cannot afford to purchase the expensive analytical equipment needed for drug analysis, may not have laboratory staff trained in assay development and validation, and in some cases may not have laboratories that can process and store blood samples for analysis of drugs in pharmacokinetic or pharmacodynamics studies. In addition, most clinical investigators do not have the expertise to conduct pharmacokinetic analyses. Therefore, the Clinical Pharmacology Shared Resource is providing important, accessible, and value-added services to MCC members. Under the leadership of Pamala Jacobson, PharmD, and Mark Kirstein, PharmD, the Shared Resource has consulted on and supported more than 25 studies and has developed assays to detect more than a dozen cancer drugs and their metabolites. The leaders have extensive research experience in clinical pharmacology, with expertise in stem cell transplantation and solid tumors. Day-to-day operations ofthe analytical laboratory are overseen by Mr. Jim Fisher, who has 28 years of analytical experience and has managed the laboratory since 2003. Within the past 2 years, an external advisory board was established, new staff were hired to improve the timeliness of sample analysis and assay development, and new instruments were purchased. As a result, use and recognition ofthe Clinical Pharmacology Shared Resource have increased among MCC members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA077598-16
Application #
8633125
Study Section
Subcommittee G - Education (NCI)
Project Start
1998-06-01
Project End
2019-01-31
Budget Start
2014-03-05
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$128,893
Indirect Cost
$61,605
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Jaramillo, Ericka G; Mupere, Ezekiel; Opoka, Robert O et al. (2017) Delaying the start of iron until 28 days after antimalarial treatment is associated with lower incidence of subsequent illness in children with malaria and iron deficiency. PLoS One 12:e0183977
Pang, Jiuxia; Shen, Na; Yan, Fei et al. (2017) Thymoquinone exerts potent growth-suppressive activity on leukemia through DNA hypermethylation reversal in leukemia cells. Oncotarget 8:34453-34467
Lin, Weiming; Modiano, Jaime F; Ito, Daisuke (2017) Stage-specific embryonic antigen: determining expression in canine glioblastoma, melanoma, and mammary cancer cells. J Vet Sci 18:101-104
Winterhoff, Boris J; Maile, Makayla; Mitra, Amit Kumar et al. (2017) Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells. Gynecol Oncol 144:598-606
Boylan, Kristin L M; Buchanan, Petra C; Manion, Rory D et al. (2017) The expression of Nectin-4 on the surface of ovarian cancer cells alters their ability to adhere, migrate, aggregate, and proliferate. Oncotarget 8:9717-9738
Zhao, Xianda; Li, Lihua; Starr, Timothy K et al. (2017) Tumor location impacts immune response in mouse models of colon cancer. Oncotarget 8:54775-54787
Lynn, Geoffrey E; Oliver, Jonathan D; Cornax, Ingrid et al. (2017) Experimental evaluation of Peromyscus leucopus as a reservoir host of the Ehrlichia muris-like agent. Parasit Vectors 10:48
Luangphakdy, Viviane; Elizabeth Pluhar, G; Piuzzi, Nicolás S et al. (2017) The Effect of Surgical Technique and Spacer Texture on Bone Regeneration: A Caprine Study Using the Masquelet Technique. Clin Orthop Relat Res 475:2575-2585
Guspiel, Amanda; Menk, Jeremiah; Streifel, Andrew et al. (2017) Management of Risks From Water and Ice From Ice Machines for the Very Immunocompromised Host: A Process Improvement Project Prompted by an Outbreak of Rapidly Growing Mycobacteria on a Pediatric Hematopoietic Stem Cell Transplant (Hsct) Unit. Infect Control Hosp Epidemiol 38:792-800
Mallhi, K; Orchard, P J; Miller, W P et al. (2017) Non-myeloablative conditioning for second hematopoietic cell transplantation for graft failure in patients with non-malignant disorders: a prospective study and review of the literature. Bone Marrow Transplant 52:726-732

Showing the most recent 10 out of 957 publications